UCB 35440Alternative Names: UCB 35440-3
Latest Information Update: 05 Aug 2004
At a glance
- Originator UCB
- Class Antiallergics; Antiasthmatics; Piperazines
- Mechanism of Action 5-lipoxygenase inhibitors; Histamine H1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Allergic rhinitis; Asthma